
The review critically evaluates the preclinical molecular pharmacology of nelarabine, the only T-cell acute lymphoblastic leukemia (T-ALL) specific drug in clinical use. While nelarabine's active metabolite, ara-G triphosphate, targets nuclear DNA synthesis, unresolved questions remain on its DNA lesions, repair mechanisms, and additional cellular targets. The review emphasizes the need for further research into nelarabine’s combination therapies and future mechanisms for enhancing its efficacy and reducing toxicity in T-ALL treatment.
Like
Save
Share